Novartis AG
IL-17 ANTAGONISTIC ANTIBODIES

Last updated:

Abstract:

An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

Status:
Application
Type:

Utility

Filling date:

15 May 2019

Issue date:

5 Sep 2019